• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Immune Checkpoint Inhibitor plus Anti-VEGF/TKI Combined with Transarterial Chemoembolization in Locally Advanced Nonmetastatic Hepatocellular Carcinoma: Real-World Treatment Strategy Based on Phase 3 Clinical Trial Results.

作者信息

Kudo Masatoshi

机构信息

Department of Gastroenterology and Hepatology, Kindai University Faculty of Medicine, Osaka, Japan.

出版信息

Liver Cancer. 2025 Mar 29;14(3):241-247. doi: 10.1159/000545594. eCollection 2025 Jun.

DOI:10.1159/000545594
PMID:40308722
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC12043110/
Abstract
摘要
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0e6c/12043110/e62a3035c8b5/lic-2025-0014-0003-545594_F03.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0e6c/12043110/94169cef0277/lic-2025-0014-0003-545594_F04.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0e6c/12043110/342f8305db99/lic-2025-0014-0003-545594_F01.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0e6c/12043110/2b2fe309e392/lic-2025-0014-0003-545594_F02.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0e6c/12043110/e62a3035c8b5/lic-2025-0014-0003-545594_F03.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0e6c/12043110/94169cef0277/lic-2025-0014-0003-545594_F04.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0e6c/12043110/342f8305db99/lic-2025-0014-0003-545594_F01.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0e6c/12043110/2b2fe309e392/lic-2025-0014-0003-545594_F02.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0e6c/12043110/e62a3035c8b5/lic-2025-0014-0003-545594_F03.jpg

相似文献

1
Immune Checkpoint Inhibitor plus Anti-VEGF/TKI Combined with Transarterial Chemoembolization in Locally Advanced Nonmetastatic Hepatocellular Carcinoma: Real-World Treatment Strategy Based on Phase 3 Clinical Trial Results.免疫检查点抑制剂联合抗血管内皮生长因子/酪氨酸激酶抑制剂与经动脉化疗栓塞术用于局部晚期非转移性肝细胞癌：基于3期临床试验结果的真实世界治疗策略
Liver Cancer. 2025 Mar 29;14(3):241-247. doi: 10.1159/000545594. eCollection 2025 Jun.
2
A Changing Role of Transarterial Chemoembolization in the Era of Immune Checkpoint Inhibitor plus Anti-VEGF/TKI plus Transarterial Chemoembolization: From Total Embolization to Partial Embolization (Immune Boost Transarterial Chemoembolization).经动脉化疗栓塞术在免疫检查点抑制剂加抗血管内皮生长因子/酪氨酸激酶抑制剂加经动脉化疗栓塞术时代的角色转变：从完全栓塞到部分栓塞（免疫增强经动脉化疗栓塞术）
Liver Cancer. 2024 May 13;13(4):335-343. doi: 10.1159/000539301. eCollection 2024 Aug.
3
Vascular endothelial growth factor-targeted therapy in patients with renal cell carcinoma pretreated with immune checkpoint inhibitors: A systematic literature review.血管内皮生长因子靶向治疗在免疫检查点抑制剂预处理的肾细胞癌患者中的应用：系统文献回顾。
Cancer Treat Rev. 2024 Jan;122:102652. doi: 10.1016/j.ctrv.2023.102652. Epub 2023 Nov 4.
4
Immune checkpoint inhibitors and anti-vascular endothelial growth factor antibody/tyrosine kinase inhibitors with or without transarterial chemoembolization as first-line treatment for advanced hepatocellular carcinoma (CHANCE2201): a target trial emulation study.免疫检查点抑制剂和抗血管内皮生长因子抗体/酪氨酸激酶抑制剂联合或不联合经动脉化疗栓塞作为晚期肝细胞癌一线治疗方案（CHANCE2201）：一项目标试验模拟研究
EClinicalMedicine. 2024 May 6;72:102622. doi: 10.1016/j.eclinm.2024.102622. eCollection 2024 Jun.
5
Transarterial Chemoembolization Combined with Tyrosine Kinase Inhibitors Plus Immune Checkpoint Inhibitors Versus Tyrosine Kinase Inhibitors Plus Immune Checkpoint Inhibitors in Unresectable Hepatocellular Carcinoma with First- or Lower-Order Portal Vein Tumor Thrombosis.经动脉化疗栓塞联合酪氨酸激酶抑制剂加免疫检查点抑制剂与酪氨酸激酶抑制剂加免疫检查点抑制剂治疗不可切除的伴有一级或低级别门静脉癌栓的肝细胞癌。
Cardiovasc Intervent Radiol. 2024 Jun;47(6):751-761. doi: 10.1007/s00270-024-03724-x. Epub 2024 Apr 26.
6
Role of Transarterial Chemoembolization in the Era of Tyrosine Kinase Inhibitor and Immune Checkpoint Inhibitor Combination Therapy for Unresectable Hepatocellular Carcinoma: A Retrospective Propensity Score Matched Analysis.经动脉化疗栓塞在不可切除肝细胞癌的酪氨酸激酶抑制剂和免疫检查点抑制剂联合治疗时代的作用：回顾性倾向评分匹配分析。
Acad Radiol. 2024 Apr;31(4):1304-1311. doi: 10.1016/j.acra.2023.09.001. Epub 2023 Sep 27.
7
Efficacy and safety of first-line treatments for advanced hepatocellular carcinoma patients: a systematic review and network meta-analysis.晚期肝细胞癌患者一线治疗的疗效与安全性：一项系统评价和网状Meta分析
Front Immunol. 2024 Sep 17;15:1430196. doi: 10.3389/fimmu.2024.1430196. eCollection 2024.
8
The evolution of immune checkpoint inhibitor combinations in advanced hepatocellular carcinoma - A systematic review.免疫检查点抑制剂联合治疗晚期肝细胞癌的研究进展——系统综述。
Cancer Treat Rev. 2023 Jul;118:102584. doi: 10.1016/j.ctrv.2023.102584. Epub 2023 May 27.
9
Addition of transarterial chemoembolization improves outcome of tyrosine kinase and immune checkpoint inhibitors regime in patients with unresectable hepatocellular carcinoma.经动脉化疗栓塞术的加入可改善不可切除肝细胞癌患者酪氨酸激酶和免疫检查点抑制剂治疗方案的疗效。
J Gastrointest Oncol. 2023 Aug 31;14(4):1837-1848. doi: 10.21037/jgo-23-486. Epub 2023 Aug 14.
10
Immune checkpoint inhibitor plus tyrosine kinase inhibitor with or without transarterial chemoembolization for unresectable hepatocellular carcinoma.免疫检查点抑制剂联合酪氨酸激酶抑制剂，联合或不联合经动脉化疗栓塞术用于不可切除的肝细胞癌治疗
Front Oncol. 2025 Mar 10;15:1385304. doi: 10.3389/fonc.2025.1385304. eCollection 2025.

本文引用的文献

1
Systemic Therapy Combined with Locoregional Therapy in Intermediate-stage Hepatocellular Carcinoma.全身治疗联合局部区域治疗用于中期肝细胞癌
Interv Radiol (Higashimatsuyama). 2024 Dec 13;10:e20230035. doi: 10.22575/interventionalradiology.2023-0035. eCollection 2025 Mar 28.
2
Protocol of the IMPACT study: randomized, multicenter, phase 3 study evaluating the efficacy of immunotherapy (Atezolizumab) plus anti-VEGF therapy (Bevacizumab) in combination with transcatheter arterial chemoembolization for unresectable hepatocellular carcinoma.IMPACT研究方案：一项随机、多中心、3期研究，评估免疫疗法（阿替利珠单抗）联合抗血管内皮生长因子疗法（贝伐单抗）与经动脉化疗栓塞术联合用于不可切除肝细胞癌的疗效。
BMC Cancer. 2025 Mar 11;25(1):434. doi: 10.1186/s12885-025-13648-5.
3
Proposal of discontinuation criteria of atezolizumab plus bevacizumab after curative conversion therapy for unresectable early-to-intermediate-stage hepatocellular carcinoma: a multicenter proof-of-concept study.不可切除的早中期肝细胞癌根治性转化治疗后阿替利珠单抗联合贝伐单抗停药标准的提议：一项多中心概念验证研究
J Gastroenterol. 2025 Jun;60(6):738-753. doi: 10.1007/s00535-025-02233-z. Epub 2025 Mar 7.
4
Durvalumab with or without bevacizumab with transarterial chemoembolisation in hepatocellular carcinoma (EMERALD-1): a multiregional, randomised, double-blind, placebo-controlled, phase 3 study.度伐利尤单抗联合或不联合贝伐单抗与经动脉化疗栓塞术治疗肝细胞癌（EMERALD-1）：一项多区域、随机、双盲、安慰剂对照的3期研究。
Lancet. 2025 Jan 18;405(10474):216-232. doi: 10.1016/S0140-6736(24)02551-0. Epub 2025 Jan 8.
5
Transarterial chemoembolisation combined with lenvatinib plus pembrolizumab versus dual placebo for unresectable, non-metastatic hepatocellular carcinoma (LEAP-012): a multicentre, randomised, double-blind, phase 3 study.经动脉化疗栓塞联合乐伐替尼加帕博利珠单抗与双重安慰剂治疗不可切除、非转移性肝细胞癌（LEAP-012）：一项多中心、随机、双盲、3期研究
Lancet. 2025 Jan 18;405(10474):203-215. doi: 10.1016/S0140-6736(24)02575-3. Epub 2025 Jan 8.
6
Prognostic Value of Pathological Response for Patients with Unresectable Hepatocellular Carcinoma Undergoing Conversion Surgery.不可切除肝细胞癌患者接受转化手术时病理反应的预后价值
Liver Cancer. 2024 Jan 27;13(5):498-508. doi: 10.1159/000536376. eCollection 2024 Oct.
7
A Changing Role of Transarterial Chemoembolization in the Era of Immune Checkpoint Inhibitor plus Anti-VEGF/TKI plus Transarterial Chemoembolization: From Total Embolization to Partial Embolization (Immune Boost Transarterial Chemoembolization).经动脉化疗栓塞术在免疫检查点抑制剂加抗血管内皮生长因子/酪氨酸激酶抑制剂加经动脉化疗栓塞术时代的角色转变：从完全栓塞到部分栓塞（免疫增强经动脉化疗栓塞术）
Liver Cancer. 2024 May 13;13(4):335-343. doi: 10.1159/000539301. eCollection 2024 Aug.
8
Immune checkpoint inhibitors and anti-vascular endothelial growth factor antibody/tyrosine kinase inhibitors with or without transarterial chemoembolization as first-line treatment for advanced hepatocellular carcinoma (CHANCE2201): a target trial emulation study.免疫检查点抑制剂和抗血管内皮生长因子抗体/酪氨酸激酶抑制剂联合或不联合经动脉化疗栓塞作为晚期肝细胞癌一线治疗方案（CHANCE2201）：一项目标试验模拟研究
EClinicalMedicine. 2024 May 6;72:102622. doi: 10.1016/j.eclinm.2024.102622. eCollection 2024 Jun.
9
A Phase 2, Prospective, Multicenter, Single-Arm Trial of Transarterial Chemoembolization Therapy in Combination Strategy with Lenvatinib in Patients with Unresectable Intermediate-Stage Hepatocellular Carcinoma: TACTICS-L Trial.一项关于经动脉化疗栓塞疗法联合乐伐替尼治疗不可切除中期肝细胞癌的2期前瞻性多中心单臂试验：TACTICS-L试验
Liver Cancer. 2023 Jun 5;13(1):99-112. doi: 10.1159/000531377. eCollection 2024 Feb.
10
Effect of transcatheter arterial chemoembolization combined with lenvatinib plus anti-PD-1 antibodies in patients with unresectable hepatocellular carcinoma: A treatment with Chinese characteristics.经导管动脉化疗栓塞联合仑伐替尼加抗 PD-1 抗体治疗不可切除肝细胞癌：具有中国特色的治疗方法。
Biosci Trends. 2024 Mar 19;18(1):42-48. doi: 10.5582/bst.2023.01326. Epub 2024 Feb 8.